Open AccessIntegrated analysis of gene expression of solute carrier gene SLC19A3 with proven risk factors of microvascular complications in patients with type 2 diabetes
Author(s) -
K. P. Singh,
T. Yu. Yuzvenko
Publication year - 2021
Publication title -
klìnìčna endokrinologìâ ta endokrinna hìrurgìâ
Language(s) - English
Resource type - Journals
eISSN - 2519-2582
pISSN - 1818-1384
DOI - 10.30978/cees-2021-2-24
Subject(s) - medicine , diabetes mellitus , polyneuropathy , type 2 diabetes , peripheral neuropathy , type 2 diabetes mellitus , cohort , diabetic neuropathy , gastroenterology , endocrinology
Diabetes mellitus (DM) is a chronic progressive disorder which leads to significant disability, morbidity and is likely to progress to become one of the most widespread conditions worldwide and as an additional burden to the healthcare system already reeling under the effects of the COVID-19 pandemic worldwide. Aim — to study the correlative variation in gene expression of SLC19A3 in type 2 diabetes patients with proven risk factors of diabetes complications. Materials and methods. In the study, 190 patients with type 2 DM were screened for diabetic peripheral neuropathy (DPN). DPN was confirmed in (n = 105) patients displaying symptoms of diabetic polyneuropathy with the involvement of small nerve fibers and large nerve fibers. Out of the total cohort, 45 patients with type 2 DM were shortlisted and randomized according to the severity of diabetic polyneuropathy, for assessment of the expression of the gene SLC19A3 in stage 1 of the gene expression study.
Results. In the first stage of the study in patients with type 2 diabetes with diabetic polyneuropathy with the involvement of small nerve fibers and large nerve fibers we found that the difference in expression of the solute carrier gene SLC19A3 in patients with variable levels of neuropathy was not significant. As evident from the CT values and the value of ΔCT there was no statistically valid difference between the groups. The CT value of the target gene (SLC19A3) in all the three groups, in comparison to each other did not have significant difference in the initial phase of the investigation. In correlation to duration of disease the trend was similar, showing that duration of disease does not play an altering role in the expression of the target gene. In correlation to risk factor glycemic control (level of HbA1c) the expression of the target gene was slightly more profound in patients with an HbA1c of 9.0 %. Conclusions. Taking into consideration the results of the study it can be stated the expression of SLC19A3 is independent of the severity of diabetic polyneuropathy, duration of diabetes and the glycemic compensation in patients with type 2 diabetes.